Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Core Insights - Aura Biosciences, Inc. is set to present Phase 2 end of study data on the suprachoroidal administration of bel-sar for treating small choroidal melanoma at The Retina Society Annual Meeting in Lisbon, Portugal from September 11-15, 2024 [1] Presentation Details - The presentation titled "Final Results of a Phase 2 Trial of Suprachoroidal Administration of Belzupacap Sarotalocan (bel-sar, AU-011) for Choroidal Melanoma" will be delivered by Dr. Ivana Kim on September 12, 2024, from 11:04 am to 11:09 am Western European Daylight Time [2] - A virtual ocular oncology investor event will also be hosted by Aura on the same day at 8:00 am Eastern Time, featuring discussions on the Phase 2 end of study data [3] Company Overview - Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with its lead candidate bel-sar in late-stage clinical development for primary choroidal melanoma and other ocular oncology indications [12] - The company is also evaluating bel-sar in early-stage clinical development for bladder cancer, aiming to improve patient outcomes through vision and organ-sparing therapies [12]